TNF and neoplasm: By disturbing the cytokine balance, the anti-TNF-α and anti-IL-23 biological therapies can alter in an unpredictable measure the immune surveillance of the organism over some neoplasia existing at the time of treatment initiation but insufficiently developed to be detected with the currently available methods.